Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars ...
Am J Health Syst Pharm. 2007;64(12):1265-1273.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback